But progress – or lack thereof – with lenacapavir is a more immediate concern.
An investigator asks whether the haemophilia project, which has already been linked with toxicity concerns, should be given to elderly patients.
New data with SRP-9001 look decent, but filing plans remain uncertain.
Assets in oncology and psoriasis are set for upcoming Pdufa decisions.
Intercept looks for redemption in Nash in the third quarter, while Kymera, Zealand and Anavex hope for share price boosts.
Key upcoming clinical results approach in the third quarter for lecanemab, high-dose Eylea and Zimura.
GSK takes on arthritis and Roche aims for convenience, while Pfizer is set to report infant pneumococcal vaccine data.